share_log

Benchmark Reiterates Buy on Bio-Techne, Maintains $95 Price Target

Benzinga ·  May 2 09:55

Benchmark analyst Robert Wasserman reiterates Bio-Techne (NASDAQ:TECH) with a Buy and maintains $95 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment